BBPL’s anatomic pathology division, Boyce and Bynum Pathology Professional Services, Inc. (BBPPS), and long-term care division are not part of the transaction.
Through a separate professional services agreement, BBPPS will become the exclusive pathology provider for Quest Diagnostics clients in Missouri and a preferred pathology provider in the greater Midwestern region.
The professional services agreement will go into effect at the time the acquisition is completed, which is expected in the first quarter of 2019, subject to customary regulatory reviews. Additional financial terms of the transaction were not disclosed.
The relationship between BBPL and Quest will result in a broader menu of clinical laboratory and anatomic pathology services throughout the region. In addition, the relationship will give patients access to an expanded network of service centers across the Midwest, for greater convenience.
Quest Diagnostics, chairman, president and CEO Steve Rusckowski said: “This relationship will extend our ability to provide the most innovative, cost-efficient services to patients and providers in the nation’s heartland, deepening our presence in the region.
“It is consistent with our accelerate growth strategy, which includes delivering one to two percent in annual revenue through strategically aligned accretive acquisitions.”
Boyce and Bynum Pathology Laboratories medical director, president and CEO Dr Michael Curry said: “BBPL and Quest have complementary strengths that will improve access to superior diagnostic innovation by combining the anatomic pathology capabilities and clinical expertise of BBPPS and Quest.
“We are confident that Quest is the right organization to build on the progress and vision of BBPL to empower better health for patients in the Midwest.”
Source: Company Press Release
